Member Info for The-Hat

Result of Annual General Meeting and Completion of Placing



Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented at the end of this announcement.



Completion of Placing

Following the shareholders' vote at the AGM to authorise the Directors to allot shares for cash, the Conditional Placing announced on 12 May 2020 to raise £2,500,000 (before expenses) at 7p per share has now become unconditional. Accordingly, 35,714,286 new ordinary shares of 1p each (the "Placing Shares") will now be allotted. An application has been made for the Placing Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing ("Admission") and it is expected that Admission will become effective and that dealing in the Placing Shares will commence on or around 5 June 2020. The Placing Shares will rank pari passu with the existing ordinary shares of the Company.



Operational Update

As it has not been possible to open up the AGM to shareholder discussion in the normal way a brief update on operations and developments is provided below.

As announced on 2 June 2020, the Company has agreed a three-month extension of the collaboration with a leading global pharmaceutical company ("GlobalCo") for the successful preclinical development of the Company's lead candidate bi-specific CDX antibody. This collaboration complements the Company's own development work that is currently being undertaken. The Directors are pleased to have agreed this extension which shows GlobalCo's continuing commitment to the project despite delays created by the COVID-19 pandemic crisis which has seen the industry as a whole focussing on treatments for COVID-19 while being hampered by laboratory shutdowns over recent months.

The fundraising will also enable the Company to progress its own work on COVID-19 and other viruses considerably more intensively. The Company had already been developing treatments to be deployed against other viral pathogens prior to the onset of COVID-19. The Company's ApbHC mice have been developed in part as a discovery platform for the development of such treatments. The Directors believe, for example, that the ApbHC could potentially be used as a tool for the rapid discovery and/or isolation of human antibodies against previously unknown viruses such as the novel coronavirus or other natural or engineered human-specific pathogens, referred to in biodefence circles as "Disease X".

The funds raised will also be used to advance IND-enabling studies for HEMO-CAR-T, the Company's product candidate which is being developed for the treatment of blood cancers such as AML (acute myeloid leukaemia), particularly with the aim of creating a "tuneable and controllable drug" which would greatly enhance the safety and versatility of HEMO-CAR-T cells in relation to blood can

Is it not priced in, I would have expected a cash balance like this, not a surprise.
They will need it for all the manufacturing there planning on doing.

Well Feeks it only needs one of us to be right and were both laughing. If both of us are right then were made. lol

Hopefully, it is a great product, I just had my reservations about it. First to market does help.
Maybe I need to rethink my level of investment. I didn't attach much value to the salt.

The IP is in how they make it. You can't patent salt. Just find a way to manufacture it that doesn't infringe on the patent. If the market is as big as its suggested then food ingredient companies with billions in revenue and ready made supply chains would be all over it. I want to be wrong and If I am wrong then this has even for potential than I thought. TEK has many strings to it's bow.

I am here but not for the salt. I can't see past a one of the big food ingredient companies manufacturing nano salt once a market exists for it. Salarius are not going to have it all to themselves. Or even snapping up Salarius before their full market potential is realised. Hope I am wrong.

Yes, I am an Irish share holder and I couldn't participate in the Placing. Pee'd off

Looks like you need to be in uK to get placing shares. Primarybid will not let me register or download app.

Tried to register, appears you have to be from UK. Anyone have info on this?

In between contracts, needs to be cleaned sterilised? Longer he waited contract values going up.

If! my aunt had balls, she would be my uncle. ; )

When you saw RNS out.

I don't doubt the the potential of GDR and where it ends up and I fully intend to be a holder when it does. Sitting at nearly 300% profit and doesn't make sense not to sell now and buy back more shares later as I feel its possibly going down some more and only news will arrest it. No one has been here before this is uncharted territory for even the seasoned investor. By that I mean with the back-drop of the pandemic.

I fear it might, reality is nobody knows. I am a long term holder but I see no point in watching this drift down for days. I am trying to sell, if it goes back down then I will just buy more shares. i was in at 57 so healthy profit.

Why does there have to be an RNS?

@anon. No shame in taking a profit, no right or wrong in it. I too sold out today with a small profit just couldn't watch it anymore will probably buy back in at some point.

at 20p but after reading this mornings RNS I am going to let it ride a little longer. So much potential good news could drop any day.

AFAIK in the middle of spread so doesn't know if its a buy or a sell.
Open to be corrected.

Nothing fast track with the FDA, it will land when it lands. Happy days, climbing steadily into the news, keeps going like this might be priced in by the time we get there.

Im in here and GDR.
GDR 7m placing today and still finished up 11%.
RNS yesterday WHO recommend HCP test, a Mutli billion dollar market.
COVID play and results to come and now financed to upscale and commercialise?
Whats not to like?